Latest News and Press Releases

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March...

CALGARY, Alberta, March 26, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2025 first quarter results after the market closes on Wednesday, April 23,...

PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...

PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual...

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent...

Fourth Quarter Revenue was $519.9 million, an 8.6% increase over the prior year period Gross margin increased 15.7% to $171.7 million compared to Q4 2023 Fourth Quarter Net income was $29.2...

OSB GROUP PLC Preliminary results For the year ended 31 December 2024 LEI: 213800ZBKL9BHSL2K459 This announcement contains inside information 13 March 2025 Following the Combination with Charter...

PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...

CALGARY, Alberta, March 10, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) announces that it has filed its annual disclosure documents with the securities commissions in each of...